English
Apr. 02, 2020 - Demo of the new COVID-19 dedicated protocol
This protocol incudes many clinical key points, particularly about screening, analysis of the pathological stages as well as clinical evolutions.
Watch the replay >
Jun. 26, 2019 - PI-RADS, what's new!? - New elements to improve detection, localization, characterization and risk stratification
During this webinar we will discuss the new features of this standard in the image data acquisition, the interpretation criteria and the role of the biparametric MRI.
Watch the replay >
Press releases
Oct. 08, 2020 - Partial renewal and strengthening of the board of directors
Intrasense announces following a Board meeting on October 8th, 2020, a partial renewal and strengthening of its composition. Michèle Lesieur is coopted as administrator and appointed Chairman of the Board. Anne Larpin is coopted as administrator of the company. The ratification of these cooptations will be submitted to the next ordinary general meeting. Learn more >
See also
Previous
press release >
Sep. 30, 2020 - HY 2020 Consolidated Results Intrasense Group
Intrasense announces its 2020 consolidated IFRS half-year results at Group level as of June 30, 2020. Learn more >
See also
Previous
press release >
Apr. 21, 2020 - CE marking for the CT protocol dedicated to COVID-19
Intrasense announces that the scanner reading protocol dedicated to COVID-19 has obtained its CE marking as a world premiere. Learn more >
See also
Previous
press release >
Apr. 16, 2020 - New version of the COVID-19 protocol
Intrasense continues its involvement in the fight against COVID-19 and announces the availability on Friday April 17th, 2020 of a second version of its scanner reading protocol dedicated to the epidemic. Learn more >
See also
Previous
press release >
Apr. 02, 2020 - Intrasense and Compagnie de Télémédecine join forces in the fight against COVID-19
Intrasense combines its technological expertise with the clinical expertise of the Compagnie de Télémédecine (CTM Groupe) by deploying to all of the group's radiotherapy specialists the new scanner reading protocol dedicated to COVID-19. Learn more >
See also
Previous
press release >
Mar. 30, 2020 - Availability of a new COVID-19 dedicated protocol
The company announces the release and immediate availability of a specific scanner reading protocol dedicated to COVID-19. Learn more >
See also
Previous
press release >
Feb. 10, 2020 - Profitability meeting with 2019 annual results
Intrasense™ announces its 2019 annual results. Learn more >
See also
Previous
press release >
Dec. 19, 2019 - Intrasense™ announces the end of the BCS financing contract
Intrasense™ announces the end of the BCS (Bond Convertible into Shares) financing contract concluded with the Luxembourgish fund European High Growth Opportunities Securitization Fund (EHGO). Learn more >
See also
Previous
press release >
Nov. 19, 2019 - Intrasense™ showcases innovative solutions at RSNA 2019
Artificial intelligence will be highlighted on Intrasense™ booth (#6956). The new version of Myrian® platform enabling artificial intelligence to truly be embedded into the daily workflow and clinical routine.Learn more >
See also
Previous
press release >
Sep. 30, 2019 - Intrasense™ presents its innovations at JFR 2019 show
All innovations will be presented at JFR 2019 on the Intrasense ™ booth (# 213A). The new version of Myrian® as well as the XP-Mammo application will be display.Learn more >
See also
Previous
press release >
Sep. 24, 2019 - The new version of Myrian® 2.7 unveiled, many clinical innovations
This new version of Myrian® brings many clinical innovations and a new application.Learn more >
See also
Previous
press release >
Jul. 11, 2019 - 2019 Half -Year Results: strong growth in all financial indicators and convertible bonds contract suspension maintained
Achieving a positive Net Income within this first 2019 semester validates the strategic choices set by the new governance in 2018, generating profits for the first half of 2019 financial year.Learn more >
See also
Previous
press release >
Jun. 03, 2019 - Myrian® XP-Mammo has been CE marked
Myrian® XP-Mammo, can now be commercialized on the European market.Learn more >
See also
Previous
press release >
Apr. 29, 2019 - Intrasense™ and Radboudumc sign a multiyear partnership, deploying Myrian® XP-Prostate application as a worldwide reference
Myrian® XP Prostate, the new reference tool for worldwide prostate experts.Learn more >
See also
Previous
press release >
Apr. 24, 2019 - Braincarta choose Myrian® to industrialize its application
Elonav, a brand-new application dedicated to specifical needs of neurosurgeons.Learn more >
See also
Previous
press release >
Feb. 20, 2019 - Intrasense and 12 Sigma unveil their innovative artificial intelligence solutions at the ECR 2019 congress
Presentation of 3 innovative products based on Myrian® technology Learn more >
See also
Previous
press release >
Feb. 05, 2019 - Intrasense 2018 annual results bear first fruits of its new strategy
Strong growth, reaching operating balance.
Learn more >
Jan. 28, 2019 - Suspension of financing contract of bonds convertible into shares issuance
suspension of the automatic drawdowns of bounds convertible into shares (« OCA »), initially planned in the contract signed on August 27, 2018.
Learn more >
Congresses
ECR 2019
February 27-March 3, 2019
Vienna - AUSTRIA
Artificial Intelligence Hall - Booth #AI-8
RSNA 2019
December 01-05, 2019
Mc Cormick Place - Chicago - USA
Booth #6956
